Zobrazeno 1 - 10
of 136
pro vyhledávání: '"B. Stollenwerk"'
Autor:
D.M. Waterhouse, S. Rothschild, C. Dooms, B. Mennecier, F. Bozorgmehr, M. Majem, M. van den Heuvel, H. Linardou, B. Chul-Cho, R. Roberts-Thomson, I. Okamoto, N. Blais, G. Schvartsman, K. Holmskov, I. Chmielewska, M. Forster, B. Stollenwerk, C.C. Obiozor, Y. Wang, S. Novello
Publikováno v:
Journal of Thoracic Oncology. 18:S37-S38
Autor:
Carlos L. Correa-Martinez, Verena B. Stollenwerk, Annelene Kossow, Frieder Schaumburg, Alexander Mellmann, Stefanie Kampmeier
Publikováno v:
Microorganisms, Vol 7, Iss 10, p 400 (2019)
Vancomycin-resistant enterococci (VRE) are important nosocomial pathogens that require effective infection control measures, representing a challenge for healthcare systems. This study aimed at identifying risk factors associated with prolonged VRE c
Externí odkaz:
https://doaj.org/article/bb845da67ee84fffaa9f1e7368665e56
Autor:
B. Stollenwerk, K. Adachi, Shravanthi R. Gandra, Michael R. McClung, Kiyoshi Tanaka, H. Hagino, S. Silverman, M. Charokopou, B. Johnson
Publikováno v:
Osteoporosis International. 32:2011-2021
Summary This study assessed the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japan, using bone mineral density (BMD) efficacy data. Results show that
Autor:
John A. Kanis, Mata Charokopou, B. Stollenwerk, Oskar Ström, E. Söreskog, Cesar Libanati, F. Borgström, D. Willems, I. Lindberg
Publikováno v:
Osteoporosis International
Summary A novel cost-effectiveness model framework was developed to incorporate the elevated fracture risk associated with a recent fracture and to allow sequential osteoporosis therapies to be evaluated. Treating patients with severe osteoporosis af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eec0c77bab4179f2bb7eeb9e090f84a1
https://acuresearchbank.acu.edu.au/item/8x006/a-novel-economic-framework-to-assess-the-cost-effectiveness-of-bone-forming-agents-in-the-prevention-of-fractures-in-patients-with-osteoporosis
https://acuresearchbank.acu.edu.au/item/8x006/a-novel-economic-framework-to-assess-the-cost-effectiveness-of-bone-forming-agents-in-the-prevention-of-fractures-in-patients-with-osteoporosis
Autor:
H, Hagino, K, Tanaka, S, Silverman, M, McClung, S R, Gandra, M, Charokopou, K, Adachi, B, Johnson, B, Stollenwerk
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 32(10)
This study assessed the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japan, using bone mineral density (BMD) efficacy data. Results show that romosozu
Autor:
Peyman Hadji, E Hernlund, R Thoren, Eugene V. McCloskey, B. Stollenwerk, Axel Svedbom, R. Stad
Publikováno v:
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 30(9)
This study estimated the cost-effectiveness of pharmacological fracture prevention as prescribed in the five largest European countries (EU5) using the IOF reference cost-effectiveness model. Pharmacological fracture prevention as prescribed in clini
Publikováno v:
Value in Health. 23:S486
Autor:
B. Heeg, Mahmoud Hashim, Maarten J. Postma, E. Sidelnikov, Gregg C. Fonarow, G. Villa, F. Kroi, M. Gomez Montero, B. Stollenwerk, Zulkifly Abbas
Publikováno v:
Value in Health. 23:S497
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E Toth, B. Stollenwerk, F. Borgström, Oskar Ström, J. A. Kanis, Mata Charokopou, E Jonsson, Cesar Libanati
Publikováno v:
Value in Health. 21:S295